Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.46 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.46 |
| ▸ | MGLL | Q99685 | 3/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | FAAH | O00519 | 1/20 | 0.40 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.40 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.40 |
| ▸ | ELANE | P08246 | 1/20 | 0.40 |
| ▸ | PRTN3 | P24158 | 1/20 | 0.40 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | CA5A | P35218 | 1/20 | 0.40 |
| ▸ | CA9 | Q16790 | 1/20 | 0.40 |
| ▸ | GLA | P06280 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28582521 | 0.84 | TDP1 (0.45) | KMT2ATDP1PRMT5WDR77MGLL | |
| SCHEMBL8790740 | 0.82 | ALDH1A1 (0.48) | MGLLALDH1A1 | |
| SCHEMBL29426173 | 0.80 | SLC6A2 (0.49) | KMT2A | |
| SCHEMBL3691428 | 0.80 | CA2 (0.56) | KMT2APRMT5WDR77ALDH1A1PKM | |
| SCHEMBL58865 | 0.77 | PRMT5 (0.60) | TDP1PRMT5WDR77MGLLALDH1A1 | |
| SCHEMBL9844160 | 0.77 | PRMT5 (0.60) | TDP1PRMT5WDR77MGLLALDH1A1 | |
| SCHEMBL16223323 | 0.77 | KMT2A (0.41) | KMT2AALDH1A1FAAHPRSS1PRSS2 | |
| SCHEMBL12816499 | 0.77 | KMT2A (0.41) | KMT2ALMNAFAAHPRSS1PRSS2 | |
| SCHEMBL7067625 | 0.77 | KMT2A (0.47) | KMT2AALDH1A1FAAHPRSS1PRSS2 | |
| SCHEMBL7070229 | 0.77 | KMT2A (0.47) | KMT2AALDH1A1LMNAFAAHPRSS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118715301-A | Coating composition for creping paper product manufacture and method for producing the same | 索理思科技开曼公司 | 2024-09-27 | — | — | CN | claimed |
| CN-118715301-A | Coating composition for creping paper product manufacture and method for producing the same | 索理思科技开曼公司 | 2024-09-27 | — | — | CN | disclosed |
| WO-2023071921-A1 | POLYAMIDE COMPOSITE MATERIAL, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 上海金发科技发展有限公司 | 2023-05-04 | — | — | WO | disclosed |
| CN-107250189-A | Crosslinking polydiene propylamine copolymer for treating diabetes B | 建新公司 | 2017-10-13 | — | — | CN | disclosed |
| CN-101365441-B | Use of benzo-fused heterocycle sulfamide derivatives for the preparation of a medicament for lowering lipid levels and lowering blood glucose levels | JANSSEN PHARMACEUTICA NV | 2011-11-16 | — | — | CN | disclosed |
| US-7763646-B2 | Compounds for the treatment of alzheimer's disease | ELAN PHARMACEUTICALS, INC. (US) | 2010-07-27 | — | — | US | disclosed |
| CN-101443704-A | Positive photosensitive resin composition and porous film obtained therefrom | NISSAN CHEMICAL IND LTD (JP) | 2009-05-27 | — | — | CN | disclosed |
| CN-101365441-A | Use of benzo-fused heterocycle sulfamide derivatives for lowering lipid levels and lowering blood glucose levels | JANSSEN PHARMACEUTICA NV (BE) | 2009-02-11 | — | — | CN | disclosed |
| US-20060128786-A1 | Compounds for the treatment of alzheimer's disease | ELAN PHARMACEUTICALS, INC. | 2006-06-15 | — | — | US | disclosed |
| EP-1542964-A2 | COMPOUNDS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | Elan Pharmaceuticals, Inc. (US) | 2005-06-22 | — | — | EP | disclosed |
| EP-0930307-B1 | PROCESS FOR THE PREPARATION OF GLYCIDYL ETHERS | DAISO CO LTD (JP) | 2002-12-04 | — | — | EP | disclosed |
| EP-0930291-B1 | PROCESS FOR THE PREPARATION OF 3-AMINO-2-HYDROXY-1-PROPYL ETHERS | DAISO CO LTD (JP) | 2002-08-14 | — | — | EP | disclosed |
| EP-0605729-B1 | OXAZOLIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | TAIHO PHARMACEUTICAL CO LTD (JP) | 2000-07-26 | — | — | EP | disclosed |
| US-6087512-A | Process for preparation of glycidyl ether | DAISO CO., LTD. (JP) | 2000-07-11 | — | — | US | disclosed |
| US-6057476-A | Process for the preparation of 3-amino-2-hydroxy-1-propyl ethers | DAISO CO., LTD. (JP) | 2000-05-02 | — | — | US | disclosed |
| EP-0930291-A1 | PROCESS FOR THE PREPARATION OF 3-AMINO-2-HYDROXY-1-PROPYL ETHERS | DAISO CO., LTD. (JP) | 1999-07-21 | — | — | EP | disclosed |
| EP-0930307-A1 | PROCESS FOR THE PREPARATION OF GLYCIDYL ETHERS | DAISO CO., LTD. (JP) | 1999-07-21 | — | — | EP | disclosed |
| US-5480899-A | ANTILIPEMIC AGENTS | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 1996-01-02 | — | — | US | disclosed |
| EP-0605729-A1 | OXAZOLIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 1994-07-13 | — | — | EP | disclosed |
| US-5087773-A | Reacting with toluenesulfonic anhydride, contacting with telluride or selenide | SYRACUSE UNIVERSITY (US) | 1992-02-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060128786-A1 | Compounds for the treatment of alzheimer's disease | BACE1, BACE2, APP | KMT2A 3665/4885TDP1 672/4885PRMT5 1243/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.